- Home
- IQMX vs CMPS Comparison
IQMX vs CMPS Comparison
Compare IQMX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQMX | CMPS |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Finland | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IQMX | CMPS |
|---|---|---|
| Price | $8.99 | $11.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $14.33 | ★ $23.75 |
| AVG Volume (30 Days) | 215.9K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.42 | N/A |
| Revenue Next Year | $74.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.74 | $4.88 |
| 52 Week High | $15.10 | $15.87 |
Technical Indicators
Market Signals| Indicator | IQMX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 40.13 |
| Support Level | $8.74 | $10.68 |
| Resistance Level | $11.04 | $14.74 |
| Average True Range (ATR) | 0.46 | 0.57 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 6.76 | 31.79 |
Price Performance
Historical ComparisonAbout IQMX IQM Quantum Computers Oyj American Depositary Shares
IQM Quantum Computers Oyj is engaged in superconducting quantum computing and provides quantum computing systems and cloud platform access to enterprises, research institutions, high-performance computing centers, and national laboratories. Its offerings include quantum systems based on an open and modular architecture. The company has operations in Munich, Germany, and deployments across Europe, Asia, and North America.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.